Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three ... initial weight depending on the dose . The researchers examined the ...

“Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be sustained for ... their initial weight depending on the dose [1]. This new analysis focuses on ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least 3 years ... initial weight depending on the dose [1]. This new analysis focuses ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the mechanisms of action of tirzepatide – a drug known as Zepbound™ – on weight ...

Share on Pinterest Mounjaro helps maintain weight loss at 3-year landmark, study confirms. Image credit: NurPhoto/Getty Images. According to a new study, a once-weekly dose of tirzepatide can lead ...

Participants were randomly assigned either to escalation of dulaglutide to 4.5 mg or maximum tolerated dose (MTD), or to ...

Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide alone ... CB1 knock-in mice that showed significant dose-dependent weight loss. Biomarker analyses ...